GPCR targeted therapeutics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
97
NCT05260658
Safety and Tolerability of CFTX-1554 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 9, 2022
Completion: Feb 10, 2023
Loading map...